DXSP DXS International Plc

 
TIDMDXSP 
 
 
   THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") AND THE INFORMATION CONTAINED 
HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, 
IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED 
STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY 
OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION 
WOULD BE UNLAWFUL. 
 
   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE 
MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). IN ADDITION, MARKET 
SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE 
MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN 
PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. 
UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS 
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL 
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION. 
 
   DXS INTERNATIONAL PLC 
 
   Issue of Equity 
 
   DXS International plc ("DXS", the "Company"), the digital clinical 
decision support company, is pleased to confirm that, following its 
announcement on 19th February 2020, the Company has today completed the 
placing and subscription of ordinary shares to raise just over GBP 1 
million. The Company confirms that a total of 12,675,000 new ordinary 
shares were issued and admitted to trading today and that following the 
fundraising, the Company has a total of 48,256,416 ordinary shares in 
issue. 
 
   David Immelman, CEO of DXS International plc commented: "I'm delighted 
to have received this supportive funding at a high growth phase in the 
Company's development as DXS moves into scale up and further 
commercialisation." 
 
   The Directors of DXS International plc accept responsibility for this 
announcement 
 
   Contacts: 
 
 
 
 
David Immelman (Chief Executive)               01252 719800 
 DXS International plc                david@dxs-systems.com 
https://www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
City & Merchant Limited 
 David Papworth           020 7101 7676 
 
 
 
 
 
 
Corporate Broker and sole broker 
 to the Placing 
Hybridan LLP 
 Claire Louise Noyce               020 3764 2341 
 
 
   Notes to Editors 
 
   About DXS: 
 
   DXS International plc presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively and which should significantly contribute towards 
the NHS achieving its projected efficiency savings. 
 
 
 
 

(END) Dow Jones Newswires

February 26, 2020 10:45 ET (15:45 GMT)

Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni DXS (AQSE:DXSP)
Storico
Da Giu 2023 a Giu 2024